Bone marrow transplantation for nonmalignant diseases

被引:17
|
作者
Saba, N [1 ]
Flaig, T [1 ]
机构
[1] Univ Minnesota, Hennepin Cty Med Ctr, Div Hematol Oncol & Transplantat, Minneapolis, MN 55403 USA
来源
关键词
D O I
10.1089/152581602753658565
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone marrow transplantation (BMT) has emerged as a major therapeutic option for a number of nonmalignant disorders affecting the bone marrow and leading to clinical manifestations most likely affecting distant organs. Disorders such as autoimmune diseases, metabolic disorders, hemoglobinopathies, immunodeficiencies, and others have been the target of high-dose therapy and autologous or allogeneic bone marrow, stem cell, or cord blood transplantation. Successful results have been reported in a large number of these disorders. In most instances the goal of transplantation is to provide sufficient degree of marrow engraftment to allow long-term amelioration of disease phenotype. For many of these disorders, early diagnosis is crucial in achieving the desired results as transplantation becomes difficult when significant end-organ damage sets in. Major unsolved problems, including toxicity of conditioning regimens, graft-versus-host disease, and donor availability, need to be addressed. We attempt to provide a comprehensive review of BMT and discuss unique features of this modality for treatment of nonmalignant disorders.
引用
收藏
页码:377 / 387
页数:11
相关论文
共 50 条
  • [1] Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases
    Mark Leick
    Bradley Hunter
    Zachariah DeFilipp
    Bimalangshu R. Dey
    Areej El-Jawahri
    Matthew Frigault
    Steven McAfee
    Thomas R. Spitzer
    Paul O’Donnell
    Yi-Bin Chen
    Bone Marrow Transplantation, 2020, 55 : 758 - 762
  • [2] Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases
    Leick, Mark
    Hunter, Bradley
    DeFilipp, Zachariah
    Dey, Bimalangshu R.
    El-Jawahri, Areej
    Frigault, Matthew
    McAfee, Steven
    Spitzer, Thomas R.
    O'Donnell, Paul
    Chen, Yi-Bin
    BONE MARROW TRANSPLANTATION, 2020, 55 (04) : 758 - 762
  • [3] BONE-MARROW TRANSPLANTATION FOR MALIGNANT AND NONMALIGNANT DISEASE
    VOWELS, M
    TANG, RLP
    FORD, D
    MAMEGHAN, H
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1986, 16 (01): : 134 - 134
  • [4] Bone Marrow Transplantation in Nonmalignant Haematological Diseases: What Have We Learned about Thalassemia?
    Castagna, Luca
    Tringali, Stefania
    Sapienza, Giuseppe
    Bono, Roberto
    Di Maggio, Rosario
    Maggio, Aurelio
    THALASSEMIA REPORTS, 2023, 13 (02) : 122 - 130
  • [5] Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents
    Yabe H.
    Inoue H.
    Matsumoto M.
    Hamanoue S.
    Hiroi A.
    Koike T.
    Sako M.
    Fujiwara M.
    Ueda Y.
    Maruya E.
    Saji H.
    Kato S.
    Yabe M.
    International Journal of Hematology, 2004, 80 (1) : 78 - 82
  • [6] Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents
    Yabe, H
    Inoue, H
    Matsumoto, M
    Hamanoue, S
    Hiroi, A
    Koike, T
    Sako, M
    Fujiwara, M
    Ueda, Y
    Maruya, E
    Saji, H
    Kato, S
    Yabe, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (01) : 78 - 82
  • [7] MARROW TRANSPLANTATION FOR NONMALIGNANT DISORDERS
    THOMAS, ED
    NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (01): : 46 - 48
  • [8] MARROW TRANSPLANTATION FOR NONMALIGNANT DISORDERS
    THOMAS, ED
    NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (17): : 963 - 964
  • [9] Bone marrow transplantation for autoimmune diseases
    Ikehara, S
    ACTA HAEMATOLOGICA, 1998, 99 (03) : 116 - 132
  • [10] Bone marrow transplantation for metabolic diseases
    Parkman, R
    Crooks, G
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 1996, 16 (02) : 429 - &